Lipocine Inc. operates with a differentiated proprietary oral drug delivery platform that underpins its FDA-approved testosterone replacement therapy TLANDO and a suite of early-stage clinical candidates targeting CNS and metabolic diseases. The company’s recent financials show significant top-line fluctuations primarily associated with transitions in commercialization partners for TLANDO licensing rights, impacting revenue recognition and contributing to ongoing operating losses. Lipocine’s business model centers on licensing territorial commercialization rights to specialist partners, generating milestone and royalty income while maintaining development focus on a pipeline composed mostly of neuroactive steroid candidates in various early clinical stages. Key risks stem from regulatory uncertainties, dependence on licensees for market penetration, ongoing capital requirements, and the inherent challenges of commercializing novel CNS therapies. Monitoring upcoming regulatory milestones for TLANDO post-marketing commitments and clinical trial progress within the CNS pipeline will be crucial for assessing future growth trajectories.